nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Avitaminosis—Thalidomide—leprosy	0.0568	0.0757	CcSEcCtD
Acamprosate—Hypovitaminosis—Thalidomide—leprosy	0.051	0.0681	CcSEcCtD
Acamprosate—GRIN2C—nerve—leprosy	0.0361	0.144	CbGeAlD
Acamprosate—GRIN2B—nerve—leprosy	0.0286	0.114	CbGeAlD
Acamprosate—GRIN2A—nerve—leprosy	0.025	0.0997	CbGeAlD
Acamprosate—Suicide attempt—Dapsone—leprosy	0.0184	0.0246	CcSEcCtD
Acamprosate—GRIN3B—testis—leprosy	0.0172	0.0688	CbGeAlD
Acamprosate—Ascites—Thalidomide—leprosy	0.0118	0.0157	CcSEcCtD
Acamprosate—Hernia—Thalidomide—leprosy	0.0114	0.0152	CcSEcCtD
Acamprosate—GRM5—testis—leprosy	0.0109	0.0434	CbGeAlD
Acamprosate—GRM5—nervous system—leprosy	0.0107	0.0426	CbGeAlD
Acamprosate—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.0105	0.014	CcSEcCtD
Acamprosate—Hostility—Thalidomide—leprosy	0.00967	0.0129	CcSEcCtD
Acamprosate—Sexual dysfunction—Thalidomide—leprosy	0.00955	0.0127	CcSEcCtD
Acamprosate—Vesiculobullous rash—Thalidomide—leprosy	0.00955	0.0127	CcSEcCtD
Acamprosate—Suicide attempt—Thalidomide—leprosy	0.00943	0.0126	CcSEcCtD
Acamprosate—GRIN2D—tendon—leprosy	0.00929	0.0371	CbGeAlD
Acamprosate—Gastric ulcer—Thalidomide—leprosy	0.00921	0.0123	CcSEcCtD
Acamprosate—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00921	0.0123	CcSEcCtD
Acamprosate—Enlargement abdomen—Thalidomide—leprosy	0.0089	0.0119	CcSEcCtD
Acamprosate—Psoriasis—Thalidomide—leprosy	0.00852	0.0114	CcSEcCtD
Acamprosate—Hypothyroidism—Thalidomide—leprosy	0.00834	0.0111	CcSEcCtD
Acamprosate—GRIN2C—testis—leprosy	0.00828	0.0331	CbGeAlD
Acamprosate—GRIN2C—nervous system—leprosy	0.00812	0.0324	CbGeAlD
Acamprosate—Neuralgia—Thalidomide—leprosy	0.0077	0.0103	CcSEcCtD
Acamprosate—GRIN2D—testis—leprosy	0.00769	0.0307	CbGeAlD
Acamprosate—GRIN2D—nervous system—leprosy	0.00755	0.0302	CbGeAlD
Acamprosate—Metrorrhagia—Thalidomide—leprosy	0.00749	0.01	CcSEcCtD
Acamprosate—Psychotic disorder—Dapsone—leprosy	0.00741	0.00989	CcSEcCtD
Acamprosate—GRIN3A—testis—leprosy	0.00723	0.0289	CbGeAlD
Acamprosate—GRIN3A—nervous system—leprosy	0.0071	0.0284	CbGeAlD
Acamprosate—Amblyopia—Thalidomide—leprosy	0.00693	0.00925	CcSEcCtD
Acamprosate—GRIN2A—tendon—leprosy	0.00691	0.0276	CbGeAlD
Acamprosate—SLC36A1—tendon—leprosy	0.00686	0.0274	CbGeAlD
Acamprosate—GRIN1—nervous system—leprosy	0.00673	0.0269	CbGeAlD
Acamprosate—Rash pustular—Thalidomide—leprosy	0.00671	0.00895	CcSEcCtD
Acamprosate—Influenza—Dapsone—leprosy	0.00656	0.00875	CcSEcCtD
Acamprosate—Pancreatitis—Dapsone—leprosy	0.00643	0.00858	CcSEcCtD
Acamprosate—GRIN2B—nervous system—leprosy	0.00642	0.0257	CbGeAlD
Acamprosate—Accidental injury—Thalidomide—leprosy	0.00605	0.00807	CcSEcCtD
Acamprosate—Photosensitivity reaction—Dapsone—leprosy	0.00599	0.00799	CcSEcCtD
Acamprosate—Hyperbilirubinaemia—Thalidomide—leprosy	0.00589	0.00785	CcSEcCtD
Acamprosate—Thinking abnormal—Thalidomide—leprosy	0.00585	0.0078	CcSEcCtD
Acamprosate—Hyperuricaemia—Thalidomide—leprosy	0.00577	0.0077	CcSEcCtD
Acamprosate—GRIN2A—testis—leprosy	0.00572	0.0228	CbGeAlD
Acamprosate—SLC36A1—testis—leprosy	0.00568	0.0227	CbGeAlD
Acamprosate—Creatinine increased—Thalidomide—leprosy	0.00562	0.0075	CcSEcCtD
Acamprosate—GRIN2A—nervous system—leprosy	0.00561	0.0224	CbGeAlD
Acamprosate—SLC36A1—nervous system—leprosy	0.00558	0.0223	CbGeAlD
Acamprosate—Blood uric acid increased—Thalidomide—leprosy	0.00545	0.00727	CcSEcCtD
Acamprosate—Neck pain—Thalidomide—leprosy	0.00542	0.00723	CcSEcCtD
Acamprosate—Pulmonary embolism—Thalidomide—leprosy	0.00535	0.00714	CcSEcCtD
Acamprosate—Phosphatase alkaline increased—Thalidomide—leprosy	0.00535	0.00714	CcSEcCtD
Acamprosate—Eructation—Thalidomide—leprosy	0.00526	0.00701	CcSEcCtD
Acamprosate—Pharyngitis—Dapsone—leprosy	0.00521	0.00695	CcSEcCtD
Acamprosate—Colitis—Thalidomide—leprosy	0.00514	0.00685	CcSEcCtD
Acamprosate—GABRB3—eye—leprosy	0.00505	0.0202	CbGeAlD
Acamprosate—Cramps of lower extremities—Thalidomide—leprosy	0.00492	0.00656	CcSEcCtD
Acamprosate—Tinnitus—Dapsone—leprosy	0.0049	0.00653	CcSEcCtD
Acamprosate—Oesophagitis—Thalidomide—leprosy	0.00489	0.00652	CcSEcCtD
Acamprosate—Rash maculo-papular—Thalidomide—leprosy	0.00486	0.00649	CcSEcCtD
Acamprosate—Hyperkinesia—Thalidomide—leprosy	0.00467	0.00623	CcSEcCtD
Acamprosate—Mental disability—Thalidomide—leprosy	0.00464	0.0062	CcSEcCtD
Acamprosate—Lymphadenopathy—Thalidomide—leprosy	0.00455	0.00607	CcSEcCtD
Acamprosate—Thrombophlebitis—Thalidomide—leprosy	0.00449	0.00599	CcSEcCtD
Acamprosate—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00447	0.00596	CcSEcCtD
Acamprosate—Diabetes mellitus—Thalidomide—leprosy	0.00447	0.00596	CcSEcCtD
Acamprosate—Gastroenteritis—Thalidomide—leprosy	0.00438	0.00585	CcSEcCtD
Acamprosate—Deafness—Thalidomide—leprosy	0.00434	0.00579	CcSEcCtD
Acamprosate—Eczema—Thalidomide—leprosy	0.00432	0.00577	CcSEcCtD
Acamprosate—Injury—Thalidomide—leprosy	0.00423	0.00564	CcSEcCtD
Acamprosate—Renal failure acute—Thalidomide—leprosy	0.00421	0.00561	CcSEcCtD
Acamprosate—Libido decreased—Thalidomide—leprosy	0.00419	0.00559	CcSEcCtD
Acamprosate—Increased appetite—Thalidomide—leprosy	0.00414	0.00552	CcSEcCtD
Acamprosate—Amnesia—Thalidomide—leprosy	0.00414	0.00552	CcSEcCtD
Acamprosate—Dermatitis exfoliative—Thalidomide—leprosy	0.00412	0.00549	CcSEcCtD
Acamprosate—Vertigo—Dapsone—leprosy	0.00411	0.00548	CcSEcCtD
Acamprosate—Dermatitis bullous—Thalidomide—leprosy	0.00407	0.00542	CcSEcCtD
Acamprosate—Arthritis—Thalidomide—leprosy	0.004	0.00533	CcSEcCtD
Acamprosate—Cough—Dapsone—leprosy	0.00399	0.00532	CcSEcCtD
Acamprosate—Cardiac failure—Thalidomide—leprosy	0.00398	0.00531	CcSEcCtD
Acamprosate—Hyponatraemia—Thalidomide—leprosy	0.0039	0.0052	CcSEcCtD
Acamprosate—Diplopia—Thalidomide—leprosy	0.00389	0.00518	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.00389	0.00518	CcSEcCtD
Acamprosate—Disturbance in sexual arousal—Thalidomide—leprosy	0.00385	0.00514	CcSEcCtD
Acamprosate—Migraine—Thalidomide—leprosy	0.00382	0.0051	CcSEcCtD
Acamprosate—Psychotic disorder—Thalidomide—leprosy	0.00379	0.00506	CcSEcCtD
Acamprosate—Face oedema—Thalidomide—leprosy	0.00375	0.005	CcSEcCtD
Acamprosate—Tachycardia—Dapsone—leprosy	0.00364	0.00486	CcSEcCtD
Acamprosate—Blood creatinine increased—Thalidomide—leprosy	0.00364	0.00486	CcSEcCtD
Acamprosate—Liver function test abnormal—Thalidomide—leprosy	0.00359	0.00478	CcSEcCtD
Acamprosate—Dry skin—Thalidomide—leprosy	0.00356	0.00475	CcSEcCtD
Acamprosate—Orthostatic hypotension—Thalidomide—leprosy	0.00355	0.00473	CcSEcCtD
Acamprosate—GABRG2—nervous system—leprosy	0.00354	0.0141	CbGeAlD
Acamprosate—Breast disorder—Thalidomide—leprosy	0.00351	0.00468	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Thalidomide—leprosy	0.0035	0.00467	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Thalidomide—leprosy	0.00343	0.00457	CcSEcCtD
Acamprosate—Abdominal distension—Thalidomide—leprosy	0.00338	0.00451	CcSEcCtD
Acamprosate—Insomnia—Dapsone—leprosy	0.00337	0.0045	CcSEcCtD
Acamprosate—Dysphagia—Thalidomide—leprosy	0.00336	0.00448	CcSEcCtD
Acamprosate—Influenza—Thalidomide—leprosy	0.00336	0.00448	CcSEcCtD
Acamprosate—Eosinophilia—Thalidomide—leprosy	0.00332	0.00444	CcSEcCtD
Acamprosate—Pancreatitis—Thalidomide—leprosy	0.00329	0.00439	CcSEcCtD
Acamprosate—Angina pectoris—Thalidomide—leprosy	0.00327	0.00436	CcSEcCtD
Acamprosate—Bronchitis—Thalidomide—leprosy	0.00323	0.00431	CcSEcCtD
Acamprosate—GABRA1—nervous system—leprosy	0.00312	0.0125	CbGeAlD
Acamprosate—Pollakiuria—Thalidomide—leprosy	0.0031	0.00414	CcSEcCtD
Acamprosate—Erectile dysfunction—Thalidomide—leprosy	0.00309	0.00413	CcSEcCtD
Acamprosate—Photosensitivity reaction—Thalidomide—leprosy	0.00307	0.00409	CcSEcCtD
Acamprosate—Weight increased—Thalidomide—leprosy	0.00306	0.00408	CcSEcCtD
Acamprosate—Gastrointestinal pain—Dapsone—leprosy	0.00305	0.00407	CcSEcCtD
Acamprosate—Weight decreased—Thalidomide—leprosy	0.00304	0.00405	CcSEcCtD
Acamprosate—Hyperglycaemia—Thalidomide—leprosy	0.00303	0.00404	CcSEcCtD
Acamprosate—Pneumonia—Thalidomide—leprosy	0.00301	0.00402	CcSEcCtD
Acamprosate—Depression—Thalidomide—leprosy	0.00299	0.00398	CcSEcCtD
Acamprosate—Acute coronary syndrome—Thalidomide—leprosy	0.00295	0.00394	CcSEcCtD
Acamprosate—Body temperature increased—Dapsone—leprosy	0.00295	0.00393	CcSEcCtD
Acamprosate—Abdominal pain—Dapsone—leprosy	0.00295	0.00393	CcSEcCtD
Acamprosate—Myocardial infarction—Thalidomide—leprosy	0.00293	0.00391	CcSEcCtD
Acamprosate—Stomatitis—Thalidomide—leprosy	0.00292	0.00389	CcSEcCtD
Acamprosate—Sweating—Thalidomide—leprosy	0.00287	0.00383	CcSEcCtD
Acamprosate—Haematuria—Thalidomide—leprosy	0.00285	0.00381	CcSEcCtD
Acamprosate—Epistaxis—Thalidomide—leprosy	0.00282	0.00377	CcSEcCtD
Acamprosate—GABRB3—testis—leprosy	0.00277	0.0111	CbGeAlD
Acamprosate—GABRB3—nervous system—leprosy	0.00272	0.0108	CbGeAlD
Acamprosate—Rhinitis—Thalidomide—leprosy	0.00269	0.00359	CcSEcCtD
Acamprosate—Hepatitis—Thalidomide—leprosy	0.00269	0.00359	CcSEcCtD
Acamprosate—Hypoaesthesia—Thalidomide—leprosy	0.00267	0.00357	CcSEcCtD
Acamprosate—Pharyngitis—Thalidomide—leprosy	0.00267	0.00356	CcSEcCtD
Acamprosate—Oedema peripheral—Thalidomide—leprosy	0.00265	0.00353	CcSEcCtD
Acamprosate—Visual impairment—Thalidomide—leprosy	0.00259	0.00346	CcSEcCtD
Acamprosate—Tinnitus—Thalidomide—leprosy	0.00251	0.00334	CcSEcCtD
Acamprosate—Immune system disorder—Thalidomide—leprosy	0.00243	0.00324	CcSEcCtD
Acamprosate—Chills—Thalidomide—leprosy	0.00241	0.00322	CcSEcCtD
Acamprosate—Alopecia—Thalidomide—leprosy	0.00238	0.00317	CcSEcCtD
Acamprosate—Vomiting—Dapsone—leprosy	0.00237	0.00316	CcSEcCtD
Acamprosate—Mental disorder—Thalidomide—leprosy	0.00235	0.00314	CcSEcCtD
Acamprosate—Malnutrition—Thalidomide—leprosy	0.00234	0.00312	CcSEcCtD
Acamprosate—Headache—Dapsone—leprosy	0.00234	0.00312	CcSEcCtD
Acamprosate—Flatulence—Thalidomide—leprosy	0.00231	0.00308	CcSEcCtD
Acamprosate—Tension—Thalidomide—leprosy	0.0023	0.00306	CcSEcCtD
Acamprosate—Dysgeusia—Thalidomide—leprosy	0.00229	0.00306	CcSEcCtD
Acamprosate—Nervousness—Thalidomide—leprosy	0.00227	0.00303	CcSEcCtD
Acamprosate—Back pain—Thalidomide—leprosy	0.00226	0.00302	CcSEcCtD
Acamprosate—Muscle spasms—Thalidomide—leprosy	0.00225	0.003	CcSEcCtD
Acamprosate—Nausea—Dapsone—leprosy	0.00222	0.00296	CcSEcCtD
Acamprosate—Tremor—Thalidomide—leprosy	0.00219	0.00292	CcSEcCtD
Acamprosate—Ill-defined disorder—Thalidomide—leprosy	0.00217	0.0029	CcSEcCtD
Acamprosate—Anaemia—Thalidomide—leprosy	0.00216	0.00288	CcSEcCtD
Acamprosate—Agitation—Thalidomide—leprosy	0.00215	0.00287	CcSEcCtD
Acamprosate—Angioedema—Thalidomide—leprosy	0.00214	0.00285	CcSEcCtD
Acamprosate—Malaise—Thalidomide—leprosy	0.00211	0.00281	CcSEcCtD
Acamprosate—Vertigo—Thalidomide—leprosy	0.0021	0.0028	CcSEcCtD
Acamprosate—Syncope—Thalidomide—leprosy	0.0021	0.0028	CcSEcCtD
Acamprosate—Leukopenia—Thalidomide—leprosy	0.00209	0.00279	CcSEcCtD
Acamprosate—Palpitations—Thalidomide—leprosy	0.00207	0.00276	CcSEcCtD
Acamprosate—Loss of consciousness—Thalidomide—leprosy	0.00206	0.00274	CcSEcCtD
Acamprosate—Cough—Thalidomide—leprosy	0.00204	0.00272	CcSEcCtD
Acamprosate—Convulsion—Thalidomide—leprosy	0.00203	0.0027	CcSEcCtD
Acamprosate—Hypertension—Thalidomide—leprosy	0.00202	0.00269	CcSEcCtD
Acamprosate—Arthralgia—Thalidomide—leprosy	0.00199	0.00266	CcSEcCtD
Acamprosate—Chest pain—Thalidomide—leprosy	0.00199	0.00266	CcSEcCtD
Acamprosate—Myalgia—Thalidomide—leprosy	0.00199	0.00266	CcSEcCtD
Acamprosate—Anxiety—Thalidomide—leprosy	0.00199	0.00265	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00198	0.00264	CcSEcCtD
Acamprosate—Discomfort—Thalidomide—leprosy	0.00197	0.00263	CcSEcCtD
Acamprosate—Dry mouth—Thalidomide—leprosy	0.00195	0.0026	CcSEcCtD
Acamprosate—Confusional state—Thalidomide—leprosy	0.00193	0.00257	CcSEcCtD
Acamprosate—Infection—Thalidomide—leprosy	0.0019	0.00253	CcSEcCtD
Acamprosate—Shock—Thalidomide—leprosy	0.00188	0.00251	CcSEcCtD
Acamprosate—Thrombocytopenia—Thalidomide—leprosy	0.00187	0.00249	CcSEcCtD
Acamprosate—Tachycardia—Thalidomide—leprosy	0.00186	0.00249	CcSEcCtD
Acamprosate—Skin disorder—Thalidomide—leprosy	0.00185	0.00247	CcSEcCtD
Acamprosate—Hyperhidrosis—Thalidomide—leprosy	0.00185	0.00246	CcSEcCtD
Acamprosate—Anorexia—Thalidomide—leprosy	0.00182	0.00243	CcSEcCtD
Acamprosate—Hypotension—Thalidomide—leprosy	0.00178	0.00238	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Thalidomide—leprosy	0.00174	0.00232	CcSEcCtD
Acamprosate—Insomnia—Thalidomide—leprosy	0.00173	0.0023	CcSEcCtD
Acamprosate—Paraesthesia—Thalidomide—leprosy	0.00171	0.00229	CcSEcCtD
Acamprosate—Dyspnoea—Thalidomide—leprosy	0.0017	0.00227	CcSEcCtD
Acamprosate—Somnolence—Thalidomide—leprosy	0.0017	0.00226	CcSEcCtD
Acamprosate—Dyspepsia—Thalidomide—leprosy	0.00168	0.00224	CcSEcCtD
Acamprosate—Decreased appetite—Thalidomide—leprosy	0.00166	0.00221	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Thalidomide—leprosy	0.00165	0.0022	CcSEcCtD
Acamprosate—Constipation—Thalidomide—leprosy	0.00163	0.00218	CcSEcCtD
Acamprosate—Pain—Thalidomide—leprosy	0.00163	0.00218	CcSEcCtD
Acamprosate—Feeling abnormal—Thalidomide—leprosy	0.00157	0.0021	CcSEcCtD
Acamprosate—Gastrointestinal pain—Thalidomide—leprosy	0.00156	0.00208	CcSEcCtD
Acamprosate—Urticaria—Thalidomide—leprosy	0.00152	0.00202	CcSEcCtD
Acamprosate—Abdominal pain—Thalidomide—leprosy	0.00151	0.00201	CcSEcCtD
Acamprosate—Body temperature increased—Thalidomide—leprosy	0.00151	0.00201	CcSEcCtD
Acamprosate—Hypersensitivity—Thalidomide—leprosy	0.00141	0.00188	CcSEcCtD
Acamprosate—Asthenia—Thalidomide—leprosy	0.00137	0.00183	CcSEcCtD
Acamprosate—Pruritus—Thalidomide—leprosy	0.00135	0.0018	CcSEcCtD
Acamprosate—Diarrhoea—Thalidomide—leprosy	0.00131	0.00174	CcSEcCtD
Acamprosate—Dizziness—Thalidomide—leprosy	0.00126	0.00168	CcSEcCtD
Acamprosate—Vomiting—Thalidomide—leprosy	0.00121	0.00162	CcSEcCtD
Acamprosate—Rash—Thalidomide—leprosy	0.0012	0.00161	CcSEcCtD
Acamprosate—Dermatitis—Thalidomide—leprosy	0.0012	0.0016	CcSEcCtD
Acamprosate—Headache—Thalidomide—leprosy	0.0012	0.0016	CcSEcCtD
Acamprosate—Nausea—Thalidomide—leprosy	0.00113	0.00151	CcSEcCtD
